Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Comment on “ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer”

British Journal of Cancer volume 119, page 908 (2018)Cite this article

Subjects

We read the interesting paper by Roseweir et al.,1 which explored the biomarker utility of ERK and p38MAPK in colorectal cancer patients carrying a BRAF mutation. The authors identified phosphorylation of ERK and p38MAPK as a surrogate measure to predict better outcome in BRAF-mutant mismatch repair (MMR)-proficient colorectal cancer patients, who were diagnosed with stage III disease. The prognostic value for combined nuclear pERK and p38 score remained significant after multivariate analysis. The authors did not observe this association in MMR-deficient (MMR-D) BRAF-mutant colorectal cancer patients.

BRAF mutations in colorectal cancer are strongly associated with CpG Island methylator phenotype (CIMP), which leads to gene silencing due to methylation of promoter areas of certain genes.2 CIMP phenotype is known to be associated with sporadic microsatellite instability-high (MSI-H) colon cancers due to frequent methylation of MLH-1.2,3 Approximately 60% of loss of MLH-1 expression loss is attributable to BRAF mutations.3 To date, several other studies suggested that more than half of the BRAF-mutant colorectal cancer patients carry the MSI-H phenotype due to loss of MLH-1 function,4,5,6 particularly in patients with early stage disease. However, in the paper by Roseweir et al., the frequency of MSI-H tumours in BRAF-mutant stage I−III colorectal cancer patients was only 16% (27/165, Figure 2), suggesting this cohort may not represent the general BRAF-mutant colorectal cancer population (as a side note, although the authors reported 165 BRAF-mutant patients, the Kaplan Meier analyses in Figure 2 included a total of 166 patients). Relatively lower incidence of this important subset of patients might have also impacted the multivariate analysis conducted by the authors. Lastly, in the subgroup analysis of colorectal cancer patients, strong nuclear pERK1/2 pattern was significantly (P = 0.01, Table 3) less frequent in patients with MMR-D tumours. The combined nuclear pERK/p38 score was also relatively less detected in MMR-D cases with a borderline statistical significance (P = 0.065, Table 2) suggesting there may be an inverse association between MMR-D status and the pERK/p38 score. Given MMR-D colorectal cancers patients constitute a relatively larger segment of BRAF-mutant patients which is associated with better outcomes due to MSI-H phenotype,4 reported inverse relation between MSI-H and pERK/p38 score may generate further challenges regarding the applicability of this score.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Roseweir, A. K. et al. ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer. Br. J. Cancer 119, 323–329 (2018).

    Article  CAS  Google Scholar 

  2. Weisenberger, D. J. et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 38, 787 (2006).

    Article  CAS  Google Scholar 

  3. Parsons, M. T., Buchanan, D. D., Thompson, B., Young, J. P. & Spurdle, A. B. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J. Med. Genet. 49, 151–157 (2012).

    Article  CAS  Google Scholar 

  4. Samowitz, W. S. et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 65, 6063–6069 (2005).

    Article  CAS  Google Scholar 

  5. Deng, G. et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin. Cancer Res. 10, 191–195 (2004).

    Article  CAS  Google Scholar 

  6. Ogino, S. et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58, 90–6 (2008).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Burak Uzunparmak

  2. Emory University School of Medicine, Atlanta, GA, USA

    Ibrahim H. Sahin

Authors
  1. Burak Uzunparmak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ibrahim H. Sahin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ibrahim H. Sahin.

Ethics declarations

Competing interests

The authors declare no competing interests.

Note

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

Additional information

Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Uzunparmak, B., Sahin, I.H. Comment on “ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer”. Br J Cancer 119, 908 (2018). https://doi.org/10.1038/s41416-018-0279-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41416-018-0279-3

Search

Advanced search

Quick links